更新于：2024-11-15
Bisoprolol
比索洛尔
更新于：2024-11-15
概要
基本信息
药物类型 小分子化药 |
别名 Concor、Nerkardou、EMD 33 512 + [2] |
作用机制 β1-adrenergic receptor拮抗剂(β1-肾上腺素能受体拮抗剂)、β2-adrenergic receptor拮抗剂(β2-肾上腺素能受体拮抗剂) |
治疗领域 |
非在研适应症- |
非在研机构 |
最高研发阶段批准上市 |
最高研发阶段(中国)临床3期 |
特殊审评- |
登录后查看时间轴
结构
分子式C18H31NO4 |
InChIKeyVHYCDWMUTMEGQY-UHFFFAOYSA-N |
CAS号66722-44-9 |
关联
108
项与 比索洛尔 相关的临床试验Echocardiographic Study of a Single Dose Bisoprolol Versus Nebivolol in Healthy Subjects: a Randomized, Double-blind, Cross-over Study
Effect of Bisoprolol and Metoprolol in reducing heart rate in coronary CT-angiography candidates: a double-blind randomized clinical trial
STunning in Acute Myocardial Infarction - Beta Blockers, Angiotensin Converting Enzyme Inhibitors and Sodium/Glucose Cotransporter 2 Inhibitors Trial A Low Intervention Clinical Tria
100 项与 比索洛尔 相关的临床结果
登录后查看更多信息
100 项与 比索洛尔 相关的转化医学
登录后查看更多信息
100 项与 比索洛尔 相关的专利（医药）
登录后查看更多信息
1,837
项与 比索洛尔 相关的文献（医药）2024-12-01Annales de cardiologie et d'angeiologie
La fibrillation atriale à l'Hôpital Principal de Dakar au Sénégal : résultats et limites de la prise en charge
Article
作者: Tidiane, Ndao Serigne Cheikh ; Cherif, Mboup Mouhamed ; Khadidiatou, Dia ; Niang, Mboup Waly ; Marième, Diop ; Rabab, Yassine ; Madjiguène, Ka Mame
OBJECTIVES:
The aim of the study was to determine the prevalence of AF in the cardiology department of the Hospital Principal of Dakar, then to evaluate the clinical, paraclinical, etiological and evolutionary profiles of AF and finally to identify the limits of its management in our context.
PATIENTS AND METHODS:
This was a retrospective, descriptive, analytical, mono-centric study carried out at Hospital Principal of Dakar from January 2019 to August 2021. Were included, all patients admitted for atrial fibrillation, or patients who presented an atrial fibrillation during hospitalization, confirmed by electrocardiogram or long-term electrocardiographic recording during the study period.
RESULTS:
The prevalence of atrial fibrillation during the period of our study compared to the hospital population was 7.71%, with a sex ratio of 1.03. The mean age was 67.88 ± 14.09 years. We noted that 83.64% of patients had at least one cardiovascular risk factor, with 56.36% suffering from hypertension, 50.91% of sedentary person and 23.64% of diabetics. Clinically, 92.72% of the patients were symptomatic, with dyspnea predominating (70.91%). Cardiac arrhythmia was present in 85.45% of patients, and congestive heart failure in 47.27%. Long-term electrocardiographic recording was performed in 10 patients, showing 50% of paroxysmal atrial fibrillation. Sixty-three patients (57.27%) had permanent AF, twenty-three patients (20.91%) had persistent AF, fourteen patients (12.73%) had long-term persistent AF and ten patients (9.09%) had paroxysmal AF. Transthoracic echocardiography showed 57.27% of left atrial dilatation and 72.3% of reduced left ventricular ejection fraction. Etiologies for cardiac causes were dominated by dilated cardiomyopathy (21.82%), followed by ischemic heart disease (17.27%). In terms of treatment, the most commonly used molecule was bisoprolol (38.18%), followed by digoxin (21.81%). Anticoagulants were used in 85.46% of cases. Acenocoumarol alone was used in 69.09% of patients. Drug-induced cardioversion was attempted in 2 patients without success, and 4 patients benefited from external electric shock with 3 successes. Most patients had a favorable outcome, but 34.54% suffered hemodynamic complications (18.18%) and thromboembolic ones as well (16.36%). In-hospital mortality in our series was 20%. It was significantly related to heart failure, with a left ventricular ejection fraction < 35% (p < 0.001).
CONCLUSION:
Atrial fibrillation is serious because of its hemodynamic, thromboembolic and rhythmic complications. The high mortality is explained by the underlying condition, but also by the delay in management with late diagnosis and, above all, the unavailability of ablation procedures in our context.
2024-12-01Toxicology reports
Article
作者: Goffredo, B M ; Marano, M ; Perdichizzi, S ; Faraci, S ; Torroni, F ; Di Nardo, M ; Gowda, Sharada H
Introduction:
Intentional multiple drugs overdose is an often-encountered method of self-harm in adolescence. Treatments include supportive therapy, antidotes (when available) and decontamination techniques with the aim of reducing drugs absorption by the gastrointestinal system to minimize toxicity. Nevertheless, the decontamination techniques currently used, such as gastric lavage (GL), activated charcoal or whole-bowel irrigation, have a questionable effectiveness. Endoscopic gastric decontamination (EGD) treatment for massive ingestion of drugs or formation of pharmacobezoars is currently described only in anecdotal cases. Here we describe the management of an intentional drug overdose in an adolescent patient treated with EGD and the effects of this therapy on drugs pharmacokinetics.
Case report:
A 15-year-old boy was admitted in an unconscious state (Glasgow Coma Scale: 7-8) to the pediatric intensive care unit after assuming an unspecified amount of quetiapine, aspirin, bisoprolol, fluoxetine, furosemide, alprazolam, and pregabalin pills. Rapid sequence intubation was immediately performed and then the patient was treated with symptomatic therapy and GL with minimal removal of gastric material. Accounting for the type of drugs, the time elapsed from oral assumption and the unknown quantity assumed, EGD was attempted with aim of removing potential aggregate of the drugs. Serial blood samples were taken before and after EGD to measure the plasma level of the drugs. A pharmacobezoar was found and was immediately removed with EGD. The results of the drug monitoring showed that quetiapine exceeded the toxic level reported in literature indicating that it may have been the drug assumed in higher quantity by our patient. PICU stay was uneventful, and the patient was transferred to the psychiatric ward after extubation.
Discussion:
Our case shows how GL is not effective in mitigating multidrug absorption especially drugs potentially inducing pharmacobezoars. Furthermore, based on our plasma drug monitoring, we believe that early EGD should be considered in all cases of massive pill intake, prolonged release drugs that can form pharmacobezoars or in cases where a life-threatening dose cannot be excluded.
2024-12-01ADVANCES IN THERAPY
Review
作者: Chen, Zhangwei ; Qian, Juying ; Zhang, Mengjun
INTRODUCTION:
A systematic literature review and network meta-analysis was conducted on azilsartan medoxomil (AZL-M) versus other antihypertensive drugs' efficacy in hypertensive patients.
METHODS:
The search utilized English platforms, from January 2000 until December 2023, resulting in 10,380 articles being screened. Screening criteria included hypertension (mild or moderate); first-line treatment and washout periods; studies (monotherapy) with AZL-M, angiotensin type II receptor blockers (ARBs), angiotensin-converting enzyme inhibitors (ACEIs), angiotensin receptor neprilysin inhibitor (ARNIs), beta-blockers, calcium channel blockers (CCBs), and diuretics, either as intervention or comparator; and antihypertension efficacy as an outcome measure. Study design was randomized clinical trials. Efficacy variables included absolute office systolic and diastolic blood pressure (BP) reductions. A total of 21 publications provided adequate data for analysis, of which 20 studies reported both systolic and diastolic BP and one study reported only the diastolic BP.
RESULTS:
In 21 studies on systolic BP, against the common comparator placebo, the differences in systolic BP were significantly in favor of AZL-M, amlodipine, candesartan, irbesartan, nebivolol, nifedipine, olmesartan, sacubitril valsartan, telmisartan, and valsartan. The surface under the cumulative ranking curve (SUCRA) ranking shows that AZL-M 80 mg had the highest ranking, with a possibility of 93% being the best in all other included treatments. In 20 studies on diastolic BP, against the common comparator placebo, the differences in diastolic BP were significantly in favor of AZL-M, amlodipine, bisoprolol, nebivolol, olmesartan, sacubitril valsartan, telmisartan, and valsartan. The SUCRA ranking shows that AZL-M 80 mg had the highest ranking, with a possibility of 90% being the best in all other included treatments.
CONCLUSION:
AZL-M at 40 mg and 80 mg shows favorable efficacy compared to other anti-hypertensives, and the 80 mg dosage seemed to be the most efficacious of all the included treatments in reducing both office systolic and diastolic BP in patients with mild-to-moderate hypertension.
100 项与 比索洛尔 相关的药物交易
登录后查看更多信息
研发状态
10 条最早获批的记录, 后查看更多信息
登录
| 适应症 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|
| 心房颤动 | 日本 | 2013-06-28 | |
| 原发性高血压 | 日本 | 2013-06-28 |
登录后查看更多信息
临床结果
临床结果
适应症
分期
评价
查看全部结果
N/A | 515 | 獵網醖膚簾鬱築廠範壓(願襯網網餘範蓋願構構) = 築觸顧積蓋積衊觸糧醖 餘夢廠觸憲淵鹹鹹觸顧 (夢遞繭糧網壓獵醖網鏇 ) 更多 | 不佳 | 2024-08-13 | |||
Placebo | 獵網醖膚簾鬱築廠範壓(願襯網網餘範蓋願構構) = 壓醖顧壓醖廠齋蓋衊鬱 餘夢廠觸憲淵鹹鹹觸顧 (夢遞繭糧網壓獵醖網鏇 ) 更多 | ||||||
N/A | 515 | 齋簾襯憲顧糧糧夢獵鑰(積鬱製鏇鑰壓糧網蓋窪) = which was less than the MCID of 1.0 廠齋鹽願遞壓膚遞鏇膚 (襯繭窪構膚齋選鹽鏇鬱 ) 更多 | 不佳 | 2024-05-19 | |||
Placebo | |||||||
临床4期 | 5,020 | metoprolol or bisoprolol | 醖艱窪繭膚艱鏇餘醖製(夢簾夢鬱遞齋選鹹鑰繭) = 獵窪選繭範憲鬱夢顧網 廠齋觸積蓋膚簾選構鑰 (鑰夢鏇窪窪蓋網衊選鬱 ) 更多 | 不佳 | 2024-04-07 | ||
no-Beta-Blockers | 醖艱窪繭膚艱鏇餘醖製(夢簾夢鬱遞齋選鹹鑰繭) = 鑰蓋鹽艱蓋窪獵製鑰願 廠齋觸積蓋膚簾選構鑰 (鑰夢鏇窪窪蓋網衊選鬱 ) 更多 | ||||||
N/A | 200 | Bisoprolol 5 mg | 築廠艱蓋壓獵築窪鏇糧(觸範齋網餘糧鬱顧淵鏇) = 製憲襯壓鬱蓋鏇艱鏇襯 鹽鑰夢鏇築襯糧觸淵齋 (醖醖獵窪遞膚醖膚淵觸 ) 更多 | - | 2021-08-27 | ||
Metoprolol-SR 50 mg | 築廠艱蓋壓獵築窪鏇糧(觸範齋網餘糧鬱顧淵鏇) = 鏇糧膚選選醖鹹襯繭鑰 鹽鑰夢鏇築襯糧觸淵齋 (醖醖獵窪遞膚醖膚淵觸 ) 更多 | ||||||
临床4期 | 161 | (Beta-blocker) | 膚簾衊淵範襯衊鏇艱廠(顧膚糧窪衊觸積艱觸蓋) = 廠願選憲衊範蓋選衊製 願淵鬱製膚鏇範淵廠淵 (衊願蓋鑰壓遞簾構膚襯, 鹹蓋製鑰壓鏇齋鹽壓觸 ~ 憲餘製築夢襯齋憲製糧) 更多 | - | 2021-06-16 | ||
(Digoxin) | 膚簾衊淵範襯衊鏇艱廠(顧膚糧窪衊觸積艱觸蓋) = 製艱廠構鏇蓋觸範觸膚 願淵鬱製膚鏇範淵廠淵 (衊願蓋鑰壓遞簾構膚襯, 憲餘襯網製積鬱顧簾夢 ~ 衊夢鬱鹽觸積積願夢構) 更多 | ||||||
N/A | - | - | Highly dialyzable BB (HDBB) | 築夢壓壓襯蓋獵夢壓醖(窪觸鹽願衊齋顧製鹽獵): RR = 1.03 (95% CI, 0.88 ~ 1.22) 更多 | 不佳 | 2020-10-19 | |
Poorly dialyzable BB (PDBB) | |||||||
临床4期 | 20 | 醖築餘憲艱築積選網壓(膚鹽鹹鏇範積範網鏇壓) = 築壓製醖淵鏇鬱衊淵選 鹽廠構觸齋餘願鑰膚鏇 (觸範簾壓壓襯淵顧夢鑰, 襯艱願餘壓夢鬱獵網顧 ~ 選範壓窪餘範憲壓壓築) 更多 | - | 2020-01-29 | |||
N/A | 282 | 積網襯顧獵積齋憲遞糧(網構鏇鹹憲簾膚壓觸壓) = 壓獵鏇鏇鬱遞襯觸襯憲 構鹹鹽衊鏇顧築鹹築鑰 (選窪簾築憲顧艱範壓鑰 ) | - | 2019-09-03 | |||
積網襯顧獵積齋憲遞糧(網構鏇鹹憲簾膚壓觸壓) = 繭構夢廠觸築艱顧壓糧 構鹹鹽衊鏇顧築鹹築鑰 (選窪簾築憲顧艱範壓鑰 ) | |||||||
N/A | 尿毒症 维持 | - | 蓋遞鑰顧窪蓋淵積鹹遞(範鏇選餘淵範廠繭鏇遞): P-Value = 0.96 更多 | 积极 | 2019-06-13 | ||
N/A | 急性冠状动脉综合征 CYP3A5 * 1 | CYP3A5 * 3 | 102 | 鏇遞鏇獵構鬱鑰構觸鹽(夢獵窪衊壓壓築廠觸願) = 齋鬱餘窪製膚製遞積蓋 壓淵構鬱遞繭憲鏇憲淵 (鑰構蓋糧獵製窪顧襯網 ) 更多 | - | 2018-08-28 | ||
鏇遞鏇獵構鬱鑰構觸鹽(夢獵窪衊壓壓築廠觸願) = 襯築衊鹹壓鹹製襯製觸 壓淵構鬱遞繭憲鏇憲淵 (鑰構蓋糧獵製窪顧襯網 ) 更多 |
登录后查看更多信息
转化医学
使用我们的转化医学数据加速您的研究。
登录
或
药物交易
使用我们的药物交易数据加速您的研究。
登录
或
核心专利
使用我们的核心专利数据促进您的研究。
登录
或
临床分析
紧跟全球注册中心的最新临床试验。
登录
或
批准
利用最新的监管批准信息加速您的研究。
登录
或
特殊审评
只需点击几下即可了解关键药物信息。
登录
或
来和芽仔聊天吧
立即开始免费试用!
智慧芽新药情报库是智慧芽专为生命科学人士构建的基于AI的创新药情报平台，助您全方位提升您的研发与决策效率。
立即开始数据试用!
智慧芽新药库数据也通过智慧芽数据服务平台，以API或者数据包形式对外开放，助您更加充分利用智慧芽新药情报信息。
生物序列数据库
生物药研发创新
免费使用
化学结构数据库
小分子化药研发创新
免费使用